Literature DB >> 17090428

Evolution of artificial cells using nanobiotechnology of hemoglobin based RBC blood substitute as an example.

Thomas Ming Swi Chang1.   

Abstract

The original artificial red blood cells have evolved into oxygen carriers in the form of polyhemoglobin and conjugated hemoglobin. Clinical conditions requiring only oxygen carriers are responding well to these types of oxygen carriers without the need for a complete artificial red blood cell. For those conditions requiring more than just oxygen carriers, new generations of polyhemoglobin containing antioxidant enzymes are being developed. Though a complete artificial red blood cell comparable to red blood cell is still a dream, development in lipid membrane artificial red blood cells and biodegradable polymeric nano artificial red blood cells are steps towards this possibility. The many years of neglect on basic research in the area of blood substitutes have resulted in the lack of important basic knowledge needed for the rapid development of blood substitutes suitable for clinical use. This is further hampered by the mistaken conception that blood substitute is a single entity. We need to look at blood substitutes as consisting of progressively more complicated entities, e.g. oxygen carriers, oxygen carriers with antioxidant activity, and complete red blood cell substitutes. Each of these entities is not applicable to all clinical conditions, but is suitable for specific applications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17090428     DOI: 10.1080/10731190600973808

Source DB:  PubMed          Journal:  Artif Cells Blood Substit Immobil Biotechnol        ISSN: 1073-1199


  4 in total

1.  Mechanisms of slower nitric oxide uptake by red blood cells and other hemoglobin-containing vesicles.

Authors:  Ivan Azarov; Chen Liu; Hannah Reynolds; Zaharo Tsekouras; Janet S Lee; Mark T Gladwin; Daniel B Kim-Shapiro
Journal:  J Biol Chem       Date:  2011-07-30       Impact factor: 5.157

2.  Hypoxia and radiation therapy: past history, ongoing research, and future promise.

Authors:  Sara Rockwell; Iwona T Dobrucki; Eugene Y Kim; S Tucker Marrison; Van Thuc Vu
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

3.  The variant Creutzfeldt-Jakob Disease: Risk, uncertainty or safety in the use of blood and blood derivatives?

Authors:  Antonio Liras
Journal:  Int Arch Med       Date:  2008-06-23

4.  Erythroid Differentiation of Induced Pluripotent Stem Cells Co-cultured with OP9 Cells for Diagnostic Purposes.

Authors:  Juhye Roh; Sinyoung Kim; June-Won Cheong; Su-Hee Jeon; Hyun-Kyung Kim; Moon Jung Kim; Hyun Ok Kim
Journal:  Ann Lab Med       Date:  2022-07-01       Impact factor: 4.941

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.